Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06911632 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

Study acronym: MOMENTOUS
StatusRecruiting
PhaseNot applicable
SponsorTempus AI
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 37 → 40 locations Eligibility criteria expanded, about 12 words · Secondary endpoints: details revised at 2 of 2 entries Show 2 more changesShow less
    • Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 2 of 2 entries
  2. Trial sites expanded: 32 → 37 locationsv13
  3. Study sites: 30 to 32 Eligibility criteria revisedv12 Show 1 more changeShow less
    • Eligibility criteria revised

    See this version in full on ClinicalTrials.gov ↗

  4. Trial sites expanded: 25 → 30 locationsv11
  5. Trial status changed: Active, Not Recruiting → Recruiting Enrollment reduced: 1000 → 900 participants · Eligibility criteria expanded, about 17 words · Site details revised at 25 of 25 sitesv10 Show 3 more changesShow less
    • Enrollment reduced: 1000 → 900 participants
    • Eligibility criteria expanded, about 17 words
    • Site details revised at 25 of 25 sites

    See this version in full on ClinicalTrials.gov ↗

Show 8 earlier versionsHide 8 earlier versions
  1. Study sites: 24 to 25v9
  2. Study sites: 23 to 24v8
  3. Trial status: Recruiting to Active, Not Recruiting Study sites: 20 to 23v7 Show 1 more changeShow less
    • Study sites: 20 to 23
  4. Study sites: 18 to 20v6
  5. Study sites: 14 to 18v5
  6. Study sites: 11 to 14v4
  7. Study sites: 5 to 11v3
  8. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 5 · Start date changed from estimate of May 2025 to Jul 23, 2025v2 Show 2 more changesShow less
    • Study sites: 0 to 5
    • Start date changed from estimate of May 2025 to Jul 23, 2025
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Tempus AI
13 trials monitored
See all monitored trials
Hypertension
1,795 trials monitored
See 85 trials at risk
MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary hypertension.
Trial Details
NCT Number NCT06911632
Lead Sponsor Tempus AI
Collaborators: United Therapeutics
Conditions Pulmonary Hypertension, Interstitial Lung Disease (ILD)
Enrollment 900 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov